Cereno’s CS1 was well tolerated after one year in people with PAH in an expanded access program, with results consistent with ...
Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results